Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7834MR)

This product GTTS-WQ7834MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7834MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6758MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ8951MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11731MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ2021MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ4521MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ9204MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ15316MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ5184MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAT-354
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW